Zdravlje A.D. (Zdravlje) announces the signing of a license agreement with the Medicines Patent Pool (MPP) for a generic version of nirmatrelvir, the novel oral COVID-19 antiviral medicine (PF-07321332) developed by Pfizer, which is administered in combination with low dose ritonavir (PF-07321332; ritonavir).

Zdravlje is pleased to announce that as of 7 March 2022, Radmila Jakovljevic has joined our team as a Supply and Business Development Manager. Radmila will report directly to Dragan Cirkovic, Commercial Director.

Zdravlje is pleased to announce that as of 7 March 2022, Ms. Tamara Vasojevic has joined our senior management team as Group Human Resources Director, directly reporting to Kiren Naidoo (CEO).

On the occasion of the Rare Disease World Day, 28 February, Zdravlje is sharing the general public information to help raise the awareness and generate the change for the 300 million people worldwide living with a rare disease, their families and carers.

Zdravlje is pleased to announce an important expansion of our commercial capabilities in Serbia. As of 10 January, Zdravlje has added five medical representatives who will be working directly with doctors and pharmacists to provide professional support, expertise and information on our high quality product portfolio.

Zdravlje is pleased to announce that as of 1 January 2022, Mr. Semir Attar has joined our senior management team as Director of Regulatory & Public Affairs, directly reporting to Kiren Naidoo (CEO).

Zdravlje Leskovac continues its several-years’ activity aimed to support persons with disabilities as a partner to the "Cap for Handicap" Association.

Zdravlje is pleased to announce that as of 1st November 2021, Dragana Mirkovic has joined our team as a Product Manager. Dragana will report directly to Dragan Cirkovic, Commercial Director.

Approximately six months into new ownership Zdravlje A.D. (“Zdravlje”) is proud to announce the signing of a new agreement with Celltrion Healthcare Hungary Kft. (“Celltrion Healthcare”), a leading force in the biopharmaceutical industry. This agreement will make regdanvimab (CT-P59), a monoclonal antibody treatment for COVID-19, available for patients in Serbia and in the ex-Yugoslavia region.